Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2009 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Age-associated decline of MondoA drives cellular senescence through impaired autophagy and mitochondrial homeostasis.
Cell Rep. 2022 Mar 1;38(9):110444. doi: 10.1016/j.celrep.2022.110444.
Cell Rep. 2022.
PMID: 35235784
Free article.
Furthermore, we find that MondoA knockout mice have exacerbated senescence during ischemic acute kidney injury (AKI), and a decrease of MondoA in the nucleus is correlated with human aging and ischemic AKI. ...
Furthermore, we find that MondoA knockout mice have exacerbated senescence during ischemic acute kidney injury (AKI), and a decrease …
Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases.
Chuma M, Hamano H, Bando T, Kondo M, Okada N, Izumi Y, Ishida S, Yoshioka T, Asada M, Niimura T, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Kasamo S, Izawa-Ishizawa Y, Azuma M, Yanagawa H, Tasaki Y, Ishizawa K.
Chuma M, et al.
Basic Clin Pharmacol Toxicol. 2022 Dec;131(6):525-535. doi: 10.1111/bcpt.13799. Epub 2022 Oct 7.
Basic Clin Pharmacol Toxicol. 2022.
PMID: 36169161
Free article.
The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage 2 was a significant risk factor. ...
The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening …
Item in Clipboard
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
Homma Y, Yamaguchi O; Imidafenacin Study Group.
Homma Y, et al.
Int J Urol. 2009 May;16(5):499-506. doi: 10.1111/j.1442-2042.2009.02286.x. Epub 2009 Mar 29.
Int J Urol. 2009.
PMID: 19389083
Clinical Trial.
Item in Clipboard
Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: Preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial.
Yanagawa Y, Ogura M, Fujimoto E, Shono S, Okuda E.
Yanagawa Y, et al.
Curr Ther Res Clin Exp. 2004 Jan;65(1):26-33. doi: 10.1016/S0011-393X(04)90002-1.
Curr Ther Res Clin Exp. 2004.
PMID: 24936101
Free PMC article.
Item in Clipboard
Cite
Cite